#Anti-viral drugs Market

[screamingfromuz]

Hi there! I am reaching out because someone sent me a question about how to help Gazan civilians without accidentally helping Hamas or spreading more hate against Israelis. I honestly feel lost on this myself, but as far as I can tell you are someone who has done real activism in Israel. Do you have suggestions for diaspora Jews who want to help fight for peace?

So a small disclaimer to the Gaza problem. We have 2 main problems with getting aid into Gaza, the first is the limited amount of aid that is allowed in, sending more money cannot make it go in faster. Problem number 2 is that much of the physical aid ends in Hamas's hands or in the black market and there is nothing we can do with that. I have heard recommendations to wait and see who opens a field hospital on the Rafah border crossing, and donate to them. Despite that, here are some charities to help Palestinians both in and out of Gaza.

I will admit, most of my activism is focused on deradicalization on the Israeli side and solidarity work, so I had to ask around for some of those charities. Some of the groups I know of do not currently have an international donation link, so if I get more good ones, I'll make another post.

Gaza:

Medical aid for Palestinians-

Anera-

Doctors without borders-

Palestinians outside of Gaza and Peace movements:

Palestinian red Crescent- they also work in Gaza, but as the main source for Palestinian ambulances in the WB, I put them here.

mistaclim (Looking the occupation the the eye)- this group is helping to protect Palestinians from the illegal settlers

Keshet- this is a big one. they support Bedouin communities in normal times, and now they are working on getting bomb shelters to the unrecognized villages, and providing a mental health first aid line.

standing together- totally biased, as I am a member of this organization.

Women wage peace- a feminist based solidarity group

Haqel- they represents Palestinians in cases related to land ownership and access. there work is still ongoing even during the war

Center for Jewish non Violence - a diaspora org that also does a lot of work in the South Hebron Hills.

[macgyvermedical]

Magic Bullets: The Antibiotic Story

The year was 1907 and a Dr. Alfred Bertheim was trying to make arsenic less toxic to humans.

Why? Because in addition to killing humans, arsenic also kills trypanosomes- single-celled protozoa that cause the life-threatening infection trypanosomiasis. By creating a version of arsenic that still killed the protozoa, but not the human they infected, Dr. Bertheim could create a drug to treat the disease*.

This was not a fully new idea. About 50 years earlier, a drug called Atoxyl had been created in France. About 40 times less toxic than pure arsenic, it had been shown to not only successfully treat trypanosomiasis, but also the equally devastating syphilis infection.

But 40 times less toxic than pure arsenic is still not great. About 2% of people treated even one time with the drug ended up blind, among a myriad of other side effects. It was a start, but not ideal.

And Dr. Bertheim (under the direction of better-known Dr. Paul Ehrlich) was setting out to change that.

And it just so happened that the sixth compound from the sixth group he tried did so. Known as "compound 606", the new Arsphenamine could treat trypanosomiasis, relapsing fever, and syphilis very effectively- and it didn't leave its takers dead or blind.

Most of the time, at least. See, arsphenamine, also known by the brand name salvarsan, was a pain in the ass to administer. It had to be dissolved in several hundred mililiters of water under a nitrogen atmosphere to prepare it for administration. If it touched air, it would rapidly react, causing toxic byproducts that could cause liver failure, severe skin rashes, and even death.

But both trypanosomiasis and syphilis were definitely going to kill you, so it was worth the risk.

And the seed had been planted, so to say. The idea of a chemical able to kill infection-causing agents without killing the host was a true possibility for the future of medicine.

And by 1912, Neosalvarsan, a drug somewhat less effective -but far easier to administer and with significantly fewer side effects- was on the market. Over the next decade, Neosalvarsan would be responsible for a massive drop in syphilis cases worldwide.

But neither of the drugs could treat deadly infections from staph or strep or the hundreds of other bacterial or viral infections that still had no cure in the 1910's and 1920's.

Then came the first of the heavy-hitters. Bayer was a dye company when it started, and in 1932, three and a half decades after switching mostly to pharmaceuticals, chemists at Bayer were testing the company's dyes for anti-infective properties. They went through thousands of trials, finally finding a dye that could kill streptococcal bacteria without killing a mouse host.

Pre-1930s, streptococcal disease was a major problem. It caused strep throat, cellulitis, scarlet fever, childbed (purpural) fever, some forms of toxic shock syndrome, impetigo, necrotizing fasciitis, rheumatic fever, and many others. The skin infections may have been at least somewhat treatable with a hot compress, but the rest were prone to cause blindness, deafness, loss of limbs, and for many, loss of life.

In 1936, sulfonamide antibiotics changed that. Protosil, the first of the sulfonamides, became available to treat many of the infections listed above. These would be used for wound infections throughout WWII. Unfortunately, they would also cause the untimely death of nearly 100 people via the Elixer Sulfanilamide tragedy.

Sulfanilamide was a similar drug to Prontosil and was safe and effective for treating strep infections. However, when mixed with diethylene glycol (now used as standard car antifreeze) to make it into a liquid suspension, it was deadly. See this letter from a doctor who had prescribed the liquid form of the medication, not knowing it was poison:

[to read more about the Elixer Sulfanilamide Disaster, see here]

Despite the sulfanilamide tragedy, the race was on for more antibiotics. Three years before they went on the market, researchers had found evidence of bacterial resistance to sulfonamides. What would happen when these new bacteria, that didn't die when exposed to the new wonder drug, made up so much of the bacterial population?

In 1942, the Cocoanut Grove fire in Boston caused over 492 deaths and 130 injuries. The injured were among the first to receive a remarkable new drug called penicillin. The fire and the fate of the victims were publicized throughout the world, and penicillin became a household name overnight. But once again, even before it went on the market in 1943, just in time for the end of the Second World War, there was evidence of resistance.

But fortunately, the fire had been sparked. Over the next 30 years, many dozens of antibiotics would come into clinical use. If you've taken it, it probably came out between 1940 and 1970. Tetracycline, isoniazid, metronidazole, ciprofloxacin, erythromycin, vancomycin, amoxicillin, and dozens more you've never heard of.

And then? Nothing.

Well, not completely nothing, there were a couple that came out in the 1980s and a few in the early 2000s. But nothing like that 30-year golden age.

But now we're running into problems due to drug resistance. About 1.27 million people die annually directly from antibiotic resistant infection, while antibiotic resistance contributes to about 4.95 million more deaths.

The good news is that the drugs that are being made today are directly targeting those antibiotic resistant infections. In fact, as I'm writing this, a new drug (Zosurabalpin) is being tested for a bacteria called Carbapenem-resistant Acinetobacter baumannii, which up until now has had no antibiotic that works against it.

*as you may imagine for the time period, this was not necessarily a benevolent act. See, most of the reason Europeans wanted to treat trypanosomiasis in the first place was because they kept dying of it when they went to colonize Africa. And they wanted something that would give them a leg up on the people who were already there.

[mightyflamethrower]

CONTRIBUTORS

Do SSRI Antidepressants Cause Mass Shootings? A Closer Look at Decades of Evidence

This article originally appeared on midwesterndoctor.com and was republished with permission.

Guest post by A Midwestern Doctor

Story at a Glance: •SSRI antidepressants have a variety of horrendous side effects. These include sometimes causing the individual to become agitated, feeling they can’t be in their skin, turning psychotic, and occasionally becoming violently psychotic.

•During these psychoses, individuals can have out of body experiences where they commit lethal violence either to themselves or others. •As lawsuits later showed, this violent behavior (and the frequent suicides that followed it) were observed throughout the SSRI clinical trials, but were covered up by the SSRI manufacturers and then the drug regulators (e.g., the FDA). •Once the SSRIs entered the market, there has been a wave of SSRI suicides and unspeakable acts of violence. •Sadly, the idea that SSRIs could cause any of this has always been viewed as a “conspiracy theory” or “mistaking correlation with causation” because very few are aware of the extensive evidence linking SSRIs to violent and psychotic behavior—despite it now being on the warning label of those drugs. Most holistic doctors consider Selective Serotonin Reuptake Inhibitors (SSRI) anti-depressants to be one of most harmful mass-prescribed drugs on the market (it typically makes their top 5). However unlike the other drugs, which are just unsafe and ineffective, SSRIs also have a fairly unique problem—they can kill people who are not even taking the drugs. Note: other common contenders for that list are Statins, NSAIDs (e.g., ibuprofen), and acid reflux medications (proton pump inhibitors like prilosec). The harms and irrationality of those drugs are discussed here, here and here.

What follows is a revised and updated article summarizing the extreme dangers of those drugs I was requested by a few readers to write in light of recent tragic events.

The Forgotten Side of Medicine is a reader-supported publication. To receive new posts and support my work, please consider becoming a free or paid subscriber.

Upgrade to paid

Since SSRIs first entered the market, many have noticed the unusual correlation between their consumption and completely out of character violently psychotic behavior, such as extremely disturbing homicides or suicides being committed by the individual. As the years have gone by, more and more evidence has accumulated (e.g., through lawsuits against the drug companies) that SSRIs cause psychotic violence, and in parallel, as the usage of these drugs has spiked, more and more grisly killings have occurred. Note: a minority of people who take SSRIs greatly benefit from them (particularly those who have deficient methylation), while others (particularly those who have excessive methylation or deficient liver metabolism of SSRIs) tend to have the worst reactions (e.g., violent psychosis). While this is relatively easy to screen for, because there is a general unwillingness to acknowledge that SSRIs could be dangerous, almost no one in the medical field assess for this prior to starting the drugs or changing their dosages. That subject is discussed further here.

As you might imagine, there are many taboo areas in medicine (e.g., suggesting that vaccines can cause neurological damage to children). However, out of all of them, I’ve found by far the most hostility is directed towards anyone who insinuates mass shootings may be linked to SSRIs (e.g., I got in quite a bit of professional trouble for doing this in the past).

One of the first articles I wrote on Substack (on 5-27-22) was about this topic. It went viral and since then I’ve noticed there has gradually been more and more people who have been willing to speak out on it. I attribute this to the current political climate (the Trump presidency and the vaccine mandates has made conservatives much more willing to question both big media and big Pharma) being one where this message wanted to be heard and other conservative commentators seeing a large audience for it existed .

Note: I edited out the political commentary from this segment. The full version of it can be viewed here.

Since that time, other prominent conservatives have spoken out on this issue (e.g., Rep. Marjorie Taylor Greene). Conversely, the horror of the “far-right hysteria against SSRIs” has become a talking point of the left (e.g., see this Huffington Post piece and this Slate piece)—something I suspect is due to the high rates of psychiatric medication usage in the modern left and big Pharma buying out the Democratic party during Obama’s presidency.

Fortunately, those attacks did not work, and the violent risks of SSRI’s have gradually become more acceptable to talk about (e.g., RFK Jr. has mentioned them during his presidential campaign and not backed down when challenged on the point). In turn, each time a mass shooting happens, the same script is repeated (we need to ban all guns and have more mental health care [i.e. psyche meds] for everyone). Fortunately, this script is losing its appeal and SSRIs are more and more frequently being mentioned each time a mass shooting happens.

[xtruss]

EL LOCO! Tantric Sex and Dog Cloning: A Guide to Argentina’s Trash Trumpy New President

Leftist-hating Libertarian Javier Milei won the Nation's Presidency in a Runoff Election Sunday Night. The Former American President, Donald J. Trump, is a Big Fan

— By Nikki McCann Ramirez | Rollingstone | November 20, 2023

Javier Milei speaks to supporters after winning the Presidential election runoff at his party headquarters in Buenos Aires, Argentina on November 19, 2023. Luis Robayo/AFP/Getty Images

Argentina has elected a self-described anarcho-capitalist libertarian Javier Milei as its next president. The result of Sunday’s runoff election will mean sweeping changes to the second-largest economy in South America, which will now be helmed by one of the most bizarre figures in modern politics.

An economist-turned-legislator, Milei’s abrasive political stylings, unruly mop of hair, anti-communist ravings, and taste for conspiracies have earned him comparisons to Donald Trump, and support from right-wing figures within American media and international politics.

While wielding chainsaws as campaign props and sporting “Make Argentina Great Again” hats, Milei, nicknamed “El Loco,” has promised drastic cuts to government spending and social programs in order to curb skyrocketing inflation. As Argentina braces for what promises to be one of its most consequential presidencies in decades, here’s what you need to know about Javier Milei.

He’s an Anarcho-Capitalist Libertarian … Most of the Time

Basically, Milei wants a much, much, much, smaller government, charged only with the maintenance of justice and state security. In a viral video, Milei was filmed ripping tags with the names of a slew of government agencies off of a whiteboard. The ministries on his chopping block include: Education (“Indoctrination”); Culture; Environment and Sustainable Development; Women, Genders and Diversity; Public Works; Science, Technology and Innovation; Transportation; Health; and Social development.

They are all “out,” as he put it, “Even if [they] resist.”

As a libertarian, Milei supports the legalization of sex work, increased civilian access to guns, and the decriminalization of drugs. He has also stated that he is largely indifferent to same-sex marriage and issues of gender expression. However, his commitment to personal freedoms has been described as inconsistent when compared to his ultra-conservative views on abortion, which he opposes in virtually all circumstances, including instances of rape. Earlier this year, Milei proposed Argentina hold a referendum to overturn the law that established a right to abortion in 2020.

He Says He’s a Tantric Sex Guru

Milei’s journey into politics began largely through appearances on various Argentinian TV channels. In one interview, Milei revealed that he was not only a libertarian in an economic sense but also in his personal life.

“Yes, yes, yes,” Milei responded when asked if he supported open relationships and non-monogamy, adding that in his view, relationships should operate under the same principles of competition as the free market. “I don’t like monopolies,” he said.

In another interview, Milei spoke openly about having had threesomes and previously working as a tantric sex coach. At one point Milei revealed that through his tantra practice, he was able to hold off ejaculation for up to three months.

Interestingly enough, Milei considered comprehensive sex education to be a form of socialist indoctrination by the left.

He Cloned his Dead Dog and Consults the Clones for Political Advice

Milei considered his now-deceased English Mastiff Conan (named after Conan the Barbarian) his child, so much so that he had him cloned. Milei now owns four of those cloned mastiffs, one named after the original Conan and the others after famous conservative economists. He considers the clones his grandchildren. In his view, cloning is a way to “approach eternity.”

The president-elect dedicated his victory on Sunday to his fur babies, but it’s not the first time Conan and his progeny have been referenced as an integral part of his campaign. Milei revealed earlier this year that he communicates with his four-legged children via a mystic and that each dog serves a distinct advisory role.

Milei has also indicated that through his medium, he has been able to communicate with famous economists like Murray Rothbard and Ayn Rand. He’s even claimed to have communicated with God, who convinced him to launch a career in politics.

He Supports the Sale of Human Organs, and Maybe Kids

Free-market-loving Milei has indicated his support for private sale of human organs.

In June of last year, Milei stated that he would legalize the sale of organs, which is currently illegal in Argentina: “If you have your daughter about to die, and you need to pay for a [medical] intervention. If someone wants to buy your kidney and you could sell it to them. The solution is very painful, you are giving up an organ and, if you also add state regulations, it is worse. I’m talking about social cooperation and voluntary exchanges. It’s the decision of individuals.”

“If liberalism is the unrestricted respect for the life of others, based on the principle of non-aggression and in defense of the right to life, freedom and property; and my first property is my body, then why shouldn’t I be able to do what I want with my body?” he said in another interview.

The comments generated controversy as Milei was essentially suggesting that an individual sell a kidney and undergo invasive surgery in order to afford a separate life-saving medical procedure for a loved one. Additionally, the black market trade of organs has frequently been associated with organized crime in many South American countries, and often results in the exploitation of poor individuals.

What Milei was willing to see on the free market once again generated controversy when he suggested that he might be open to the sale of children. In 2022, when asked if he would support the right to sell one’s kids, Milei responded “it depends.”

He clarified that while he personally wouldn’t sell a child, it’s all a matter of context. “It is not what Argentine society is discussing, perhaps 200 years from now,” he added.

Milei later claimed that his comments had been misrepresented, and that he was “obviously not in favor of the sale of children.”

He’s an Anarcho-Capitalist Libertarian … Most of the Time

Basically, Milei wants a much, much, much, smaller government, charged only with the maintenance of justice and state security. In a viral video, Milei was filmed ripping tags with the names of a slew of government agencies off of a whiteboard. The ministries on his chopping block include: Education (“Indoctrination”); Culture; Environment and Sustainable Development; Women, Genders and Diversity; Public Works; Science, Technology and Innovation; Transportation; Health; and Social development.

They are all “out,” as he put it, “Even if [they] resist.”

As a libertarian, Milei supports the legalization of sex work, increased civilian access to guns, and the decriminalization of drugs. He has also stated that he is largely indifferent to same-sex marriage and issues of gender expression. However, his commitment to personal freedoms has been described as inconsistent when compared to his ultra-conservative views on abortion, which he opposes in virtually all circumstances, including instances of rape. Earlier this year, Milei proposed Argentina hold a referendum to overturn the law that established a right to abortion in 2020.

He Says He’s a Tantric Sex Guru

The president-elect dedicated his victory on Sunday to his fur babies, but it’s not the first time Conan and his progeny have been referenced as an integral part of his campaign. Milei revealed earlier this year that he communicates with his four-legged children via a mystic and that each dog serves a distinct advisory role.

Milei has also indicated that through his medium, he has been able to communicate with famous economists like Murray Rothbard and Ayn Rand. He’s even claimed to have communicated with God, who convinced him to launch a career in politics.

He Supports the Sale of Human Organs, and Maybe Kids

Free-market-loving Milei has indicated his support for private sale of human organs.

In June of last year, Milei stated that he would legalize the sale of organs, which is currently illegal in Argentina: “If you have your daughter about to die, and you need to pay for a [medical] intervention. If someone wants to buy your kidney and you could sell it to them. The solution is very painful, you are giving up an organ and, if you also add state regulations, it is worse. I’m talking about social cooperation and voluntary exchanges. It’s the decision of individuals.”

“If liberalism is the unrestricted respect for the life of others, based on the principle of non-aggression and in defense of the right to life, freedom and property; and my first property is my body, then why shouldn’t I be able to do what I want with my body?” he said in another interview.

The comments generated controversy as Milei was essentially suggesting that an individual sell a kidney and undergo invasive surgery in order to afford a separate life-saving medical procedure for a loved one. Additionally, the black market trade of organs has frequently been associated with organized crime in many South American countries, and often results in the exploitation of poor individuals.

What Milei was willing to see on the free market once again generated controversy when he suggested that he might be open to the sale of children. In 2022, when asked if he would support the right to sell one’s kids, Milei responded “it depends.”

He clarified that while he personally wouldn’t sell a child, it’s all a matter of context. “It is not what Argentine society is discussing, perhaps 200 years from now,” he added.

Milei later claimed that his comments had been misrepresented, and that he was “obviously not in favor of the sale of children.”

He’s a Fan of Fascist Trump, and Fascist Trump is a Fan of Him

Following Milei’s victory on Sunday, Trump congratulated him on Truth Social. “Congratulations to Javier Milei on a great race for President of Argentina. The whole world was watching! I am very proud of you,” the former president wrote. “You will turn your Country around and truly Make Argentina Great Again!”

It’s true that Milei has embraced his own version of MAGA politics, and even sported his own “Make Argentina Great Again” hats.

A staunch populist who pulled off a dark horse bid for the presidency amidst a wave of public ire at the establishment, the comparisons between Trump and Milei are plain to see, with uniquely bizarre hairstyles to boot. Milei followed one of Trump’s most infamous tactics in his own rise to the presidency: preemptively claiming election interference to guard against a potential loss.

Milei has expressed his desire to improve the relationship between the United States, and with Trump remaining the clear frontrunner in the Republican primaries, a future relationship with Milei could mirror Trump’s past relationship with other right-wing leaders in the Americas like Brazil’s former president, Jair Bolsonaro.

He REALLY Hates the Left

Milei is, at heart, a culture warrior. A soldier in the batalla cultural unfolding in Latin America and South America, Milei, like many of the American right’s most staunch culture warlords, is bitterly antagonistic to leftist politics.

“Leftist sons of whores,” “shit leftists,” and “filthy leftists” are just some of the descriptors Milei uses to describe his political opposition, and much of his rhetoric regarding progressive values is practically a word-for-word translation of the kind of language used by the American right.

Milei accuses “cultural Marxists” of promoting feminism, environmental sustainability, gender ideology, diversity initiatives, and social welfare that (in his opinion) will inevitably turn Argentina into a socialist hellscape. Sound familiar?

“You can’t give leftist pieces of shit even a millimeter because if you give them a millimeter they will use it to destroy you,” he exclaimed in a now-viral interview earlier this year. In his own political platform, Milei has promised to take the metaphorical chainsaw to Argentinian government bodies and organizations who he sees as the most prominent promoters of leftist ideology.

[pandemic-info]

Vaccines currently in development

(I did not create this list and I'm sorry I don't know the original OP who compiled it.)

These are all currently in development to come to market in the next 2 years. If just one really works it will be a game changer

MT-001 a novel protein component vaccine candidate, MT-001, based on a fragment of the SARS-CoV-2 spike protein that encompasses the receptor binding domain (RBD) | A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response - https://www.mdpi.com/2076-393X/11/4/832 Mice and hamsters immunized with a prime-boost regimen of MT-001 demonstrated extremely high anti-spike IgG titers, and remarkably this humoral response did not appreciably wane for up to 12 months following vaccination. Further, virus neutralization titers, including titers against variants such as Delta and Omicron BA.1, remained high without the requirement for subsequent boosting.

DCFHP a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. | A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110616/#MOESM3

ISM3312 a COVID-19 drug entirely designed by generative AI works by inhibiting a protein called 3CL protease — a critical factor in viral replication and a popular target for anti-COVID drugs. Unlike similar therapeutics, it works on a very broad spectrum — showing efficacy not only against all current COVID variants, but also coronaviruses other than SARS-CoV-2. As such, it may possess the ability to resist future mutations, providing a solution to drug-resistant strains. | ‘It’s perfect’: World’s first generative AI-designed COVID drug to start clinical trials https://www.thestar.com/news/canada/2023/02/23/its-perfect-worlds-first-generative-ai-designed-covid-drug-to-start-clinical-trials.html

BNT162b4, composed of a T cell antigen mRNA encoding for SARS-CoV-2 non-spike proteins that are highly conserved across a broad range of SARS-CoV-2 variants and will be evaluated in combination with the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine | Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-advance-next-generation-covid-19-vaccine

25F9 and 20A7 identified as two highly potent broadly neutralizing antibodies, making them promising prophylactic candidates against sarbecovirus infection |Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine – Science Translational Medicine – https://www.science.org/doi/10.1126/scitranslmed.adg7404

ChAd-SARS-CoV-2-BA.5-S, which encodes for a pre- fusion and surface-stabilized S protein of the BA.5 strain. | A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters https://www.biorxiv.org/content/10.1101/2023.05.04.539332v1

[credenceresearchdotblog]

The Glioblastoma Treatment Drugs Market is projected to grow from USD 2665 million in 2024 to an estimated USD 5589.2 million by 2032, with a compound annual growth rate (CAGR) of 9.7% from 2024 to 2032. Glioblastoma multiforme (GBM) is the most aggressive and common type of primary brain tumor in adults. Known for its rapid progression and resistance to standard therapies, GBM presents a significant challenge to healthcare professionals and researchers worldwide. The growing prevalence of glioblastoma, coupled with advancements in oncology, has spurred significant developments in the glioblastoma treatment drugs market.

Browse the full report at https://www.credenceresearch.com/report/glioblastoma-treatment-drugs-market

Market Overview

The glioblastoma treatment drugs market is experiencing steady growth, driven by the increasing incidence of GBM and rising investments in cancer research. According to recent statistics, the global glioblastoma treatment market was valued at approximately USD 2.1 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 8% during the forecast period of 2023–2030.

Current Treatment Options

The primary treatment for glioblastoma typically involves surgical resection, followed by radiation therapy and chemotherapy. Temozolomide (TMZ), an oral alkylating agent, remains the gold standard chemotherapy drug for GBM treatment. However, the recurrence of glioblastoma post-treatment remains a critical concern.

To address these challenges, several new drugs and therapeutic approaches are entering the market, including:

Targeted Therapies Drugs targeting specific molecular pathways, such as EGFR (epidermal growth factor receptor) inhibitors, have shown promise. Agents like bevacizumab, an anti-VEGF (vascular endothelial growth factor) monoclonal antibody, are being used to control tumor angiogenesis and prolong progression-free survival.

Immunotherapies Immunotherapy has emerged as a game-changer in oncology. Immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies are being explored to harness the body’s immune system to fight glioblastoma. Clinical trials of drugs like nivolumab are underway, aiming to improve patient outcomes.

Gene and Cell-Based Therapies Advances in gene editing and cell-based therapies have paved the way for personalized medicine in glioblastoma treatment. Oncolytic viral therapies, which use genetically modified viruses to target cancer cells, are gaining traction in research and development pipelines.

Challenges in the Market

Despite significant progress, the glioblastoma treatment drugs market faces several hurdles:

High Costs: Advanced therapies often come with a hefty price tag, limiting access for many patients.

Complex Biology of GBM: The heterogeneity and adaptability of glioblastoma tumors make them highly resistant to treatment.

Regulatory Barriers: Stringent approval processes for new drugs can delay market entry.

Future Outlook

The future of the glioblastoma treatment drugs market looks promising, driven by ongoing research and technological advancements. The integration of artificial intelligence and big data analytics in drug discovery is expected to expedite the development of effective treatments. Additionally, combination therapies that incorporate multiple approaches—such as chemotherapy, immunotherapy, and gene therapy—are likely to emerge as the new standard of care.

Government initiatives to support cancer research and increasing funding from private organizations further bolster the market’s growth potential. However, addressing the affordability and accessibility of these advanced treatments remains crucial to ensuring better outcomes for patients worldwide.

Key Player Analysis:

Amgen, Inc.

Amneal Pharmaceuticals

Arbor Pharmaceuticals, LLC

AstraZeneca PLC

Hoffmann-La Roche Ltd.

Gene Therapy

GlaxoSmithKline plc (GSK)

Glioma Steam Cell Targeting

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Kinase Inhibitor

Merck & Co., Inc.

MiRNA Targeting

Novartis AG

Pfizer Inc.

Roche Holding AG

Sanofi S.A.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Segmentation:

By Treatment 

Surgery

Radiation Therapy

Chemotherapy

Targeted Therapy

Tumor Treating Field (TTF) Therapy

Immunotherapy

By Drug Class:

Antineoplastic

VEGF/VEGFR Inhibitors

Alkylating Agents

Miscellaneous Antineoplastic

By Distribution Channel:

Hospitals

Cancer Research Organizations

Long Term Care Centers

Diagnostic Centers

By Region:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/glioblastoma-treatment-drugs-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com 

[prasad213]

Wholesale pharmacy in India

Vaccinating people continues to be a challenge all over the world. The major reason is the shortage of vaccines as production has slowed down. Many developing countries still rely on generic medicine exporters in India as a world leader to meet their shortages. India still produces nearly 50% of the required vaccines.

Lotus International is a wholesale pharmacy in India which is helping the global pharma industry to continue with its immunization programs.

Overview of vaccines from India

All children in this world require affordable vaccinations to remain healthy and immunized. They are required to avoid other health-related problems. Vaccinations are still being given for hepatitis B, rubella, diphtheria, measles, mumps and tetanus. Viral diseases like Chikungunya, Zika, hepatitis B, rotavirus and typhoid also require to be stopped. The other vaccines are now being given full attention with cell-based and genetic technologies.

In the last two years, the injections were being made to stop coronavirus. However now the focus is shifting back to developing other inoculations. As a wholesale pharmacy in India, Lotus international has already scaled its production capacity to meet the shortages. The country has several big and small manufacturing companies to produce different injections. As licenses are being renewed they will be sent across to different countries.

India’s strong track record as a vaccine supplier

For a long time, it has been possible for generic medicine exporters in India to deliver cheap medicines. When the AIDS epidemic crossed its limits in Africa, Indian medicines were more popular. They were not only cheap but also effective for the growing number of patients.

The other compelling reasons for India to be a leader are:

Valued R & D center with the manufacturing units. These are the hubs where innovations and experiments are conducted.

Many world pharma companies outsource their needs to Indian companies.

Quality has never been questioned in the world markets.

By sending the latest COVID-19 vaccines, Indian companies have proved they can be relied upon to make emergency vaccines.

High volumes with low costs have been the mantra for successful formulas to work in India’s favor.

The wholesale pharmacy in India has been able to donate vaccines to countries to compete with Russia and China.

Why does Lotus International continue to manufacture and supply?

As a wholesale pharmacy in India, we continue to make antiviral medicines for the domestic and international requirements. Arresting viral infections that can be life-threatening is critical as they rapidly grow. Primarily, our vaccines continue to help people in remaining healthy. As travel and restrictions are lifted our production goes full scale.

We are already supplying bulk orders of Baraclude, Cymevene, Genvir and Fortovase. Our production capacity to make anti-cancer, anti-diabetic agents, growth hormones, weight loss and hair loss products are very popular.

Lotus International is one of the leading suppliers of vaccines and other generic drugs in the world. We are ISO 9001:2015 certified company and government-recognized export house. No matter in which time zone, your pharma business is located, we can send supplies.

[sunalimerchant]

Top API Manufacturers in Gujarat: A Comprehensive Guide

Gujarat, often referred to as the "Pharmaceutical Hub of India," plays a pivotal role in the country’s pharmaceutical industry. Known for its robust infrastructure, skilled workforce, and favorable policies, the state is home to some of the top API manufacturers in Gujarat. Active Pharmaceutical Ingredients (APIs) are the core components of medicines, and Gujarat's prominence in API production has made it a crucial player in meeting global pharmaceutical demands.

This comprehensive guide explores the importance of Gujarat in API manufacturing, key strengths of its industry, and the factors driving its growth.

Why Gujarat is a Hub for API Manufacturing

1. Strategic Location

Gujarat's strategic location, with access to major ports and excellent transportation networks, facilitates the efficient export of APIs to international markets. This connectivity makes Gujarat a preferred destination for global pharmaceutical companies seeking API suppliers.

2. Government Support

The state government has introduced policies and initiatives to encourage pharmaceutical manufacturing, including tax benefits, infrastructure support, and single-window clearance for businesses. These measures have significantly boosted the growth of API manufacturers in Gujarat.

3. Advanced Infrastructure

Gujarat boasts world-class pharmaceutical zones and industrial parks equipped with state-of-the-art facilities. These include dedicated zones for chemical and pharmaceutical manufacturing, ensuring compliance with stringent quality standards.

4. Skilled Workforce

The state is home to numerous educational and research institutions, providing a steady supply of skilled professionals to the pharmaceutical industry. This expertise helps API manufacturers maintain high-quality production standards.

5. Focus on Quality and Compliance

Gujarat's API manufacturers adhere to global regulatory standards, including certifications from the US FDA, EU GMP, and WHO GMP. This focus on compliance has enhanced the state’s reputation as a trusted supplier of APIs worldwide.

Types of APIs Manufactured in Gujarat

API manufacturers in Gujarat produce a wide range of APIs catering to various therapeutic categories. Some of the key types include:

Antibiotics: APIs used in the production of essential antibiotics for bacterial infections.

Cardiovascular Drugs: APIs for medicines targeting heart diseases and blood pressure management.

Anti-Diabetic Drugs: Active ingredients used in diabetes management medications.

Analgesics and Anti-Inflammatories: APIs for pain relief and inflammation control.

Antiviral and Antifungal Drugs: Essential APIs for combating viral and fungal infections.

Top Regions for API Manufacturing in Gujarat

Several regions in Gujarat are known for their concentration of API manufacturers:

Ahmedabad: A leading pharmaceutical hub with advanced facilities and research centers.

Vadodara: Known for its industrial estates and focus on pharmaceutical manufacturing.

Ankleshwar: One of Asia’s largest chemical industrial estates, housing numerous API manufacturers.

Surat: Emerging as a prominent location for pharmaceutical production.

Vapi: An established industrial area contributing significantly to API manufacturing.

Factors Contributing to the Growth of API Manufacturers in Gujarat

1. Export Potential

API manufacturers in Gujarat have a strong export focus, supplying to markets in the US, Europe, and Asia. The state's robust infrastructure and compliance with international standards make it a reliable partner for global pharmaceutical companies.

2. Innovation and Research

Many manufacturers invest heavily in research and development to produce advanced APIs and meet evolving industry demands. This innovation helps them stay competitive in the global market.

3. Cost-Effective Production

With access to abundant raw materials and efficient production processes, Gujarat’s API manufacturers can offer high-quality products at competitive prices. This cost advantage makes them attractive to both domestic and international clients.

4. Sustainability Initiatives

Environmental regulations and a focus on sustainability have led many manufacturers to adopt eco-friendly production practices. This aligns with global efforts to reduce the environmental impact of pharmaceutical manufacturing.

Challenges Faced by API Manufacturers in Gujarat

Despite its strengths, the industry faces certain challenges:

Dependence on Imports: Some raw materials required for API production are imported, exposing manufacturers to price fluctuations and supply chain disruptions.

Regulatory Hurdles: Meeting stringent international regulations requires significant investment in infrastructure and compliance.

Competition: The global API market is highly competitive, with emerging players from other countries posing challenges to Gujarat-based manufacturers.

Conclusion

Gujarat's prominence as a hub for API manufacturers in Gujarat is well-deserved, thanks to its strategic location, skilled workforce, and commitment to quality. The state’s API manufacturers play a vital role in supporting India’s position as a leading supplier of pharmaceuticals to the world. By continuing to innovate and adapt to global demands, Gujarat’s API industry is poised for sustained growth, contributing to advancements in healthcare worldwide.

[screamingfromuz]

Gaza

disclaimer:

I have talked about it before, but getting aid to Gazans is a harder task then usually. Despite the millions that are poured into Gaza, most of it does not get to the people, and Gaza stays poor. The money is often taken by Hamas and it's leaders, each of those leaders fortune is values in the billions. What is left is used for Hamas operations, paying to the families for people who attack Israelis, and only then get to the people.

For physical aid, such as medical aid and food, we have similar problems. Hamas takes what it needs for itself, the black market takes another share. What is left is distributed mainly by UNRWA who are known to keep stocks of food in warehouses and not distribute them, and if you know who to talk to, there are places in side Israel were you can buy groceries still with the UNRWA symbol on.

This means that no matter if Israel allows all the aid in, and no matter how much money you will donate, there is a little guarantee that the aid will get to the Gazans that need it.

So what do you do?

If you know anyone personally that is in the strip and can transfer them money, do it. If you have a way to bypass the charities and help specific people, this is your best bet.

I have put here some Aid Organizations that are relatively good at getting aid directly to the people, and if I can verify more organizations I will add them. I will also add Organizations that might not provide direct aid but work for the sake of the people in Gaza.

There are field/floating hospitals on their way or next to Gaza, the moment here is a link to donate to them I will add it here.

Medical aid for Palestinians

Anera

Doctors without borders

Gisha

An Israeli NGO that works for to protect the freedom of movement of Palestinians, especially Gaza residents.

Zakat Foundation of America

NGO giving emergency relief around the world - it helped after the recent earthquakes in Turkey and Syria and helped in the US after Katrina. You can direct where you want the donation to go, with Gaza being an option.

back to the Master Post

[dhruv-blogs]

Topical Skin Infection Treatment Drug Pipeline Analysis.

Skin and soft tissue infections have an incidence of 24.8 cases per 1,000 people. Research reveals that children under the age of 5 and adults over 65 years are more prone to developing a skin infection. As a result, leading pharmaceutical companies are involved in designing a diverse range of drugs that cater to a wide spectrum of affected individuals.

Topical skin infection treatments have gained significant importance as skin infections continue to impact millions globally. With new drug developments and innovative treatment methods, the topical skin infection treatment market is witnessing substantial growth. This article explores the topical skin infection treatment drug pipeline, highlighting its dynamics, trends, recent developments, and the impact of the COVID-19 pandemic. We’ll also look at the shock wave therapy device market’s role and leading players like GlaxoSmithKline, Fraser Health, Pfizer, and Taro Pharmaceuticals USA.

Overview of Topical Skin Infection Treatment Drug Pipeline Analysis Topical treatments for skin infections are essential, as they allow targeted therapy that minimizes systemic side effects. These treatments, including creams, gels, and ointments, are used to treat various skin infections caused by bacteria, fungi, and viruses. The drug pipeline for topical skin infections is dynamic, with several promising therapies under development. https://www.expertmarketresearch.com/clinical-trials/topical-skin-infection-treatment-drug-pipeline-analysis Key Drug Types in the Pipeline:

Antibacterial Agents: Target bacterial skin infections, such as impetigo and cellulitis. Antifungal Agents: Address fungal infections like athlete's foot and ringworm. Antiviral Agents: Used for viral skin infections, including cold sores and warts. Anti-inflammatory Agents: These drugs help reduce swelling, redness, and discomfort associated with infections. The drug pipeline aims to develop effective treatments that are easy to apply, fast-acting, and suitable for all age groups, including children and the elderly.

Dynamics of Topical Skin Infection Treatment Drug Pipeline Analysis Market Drivers: https://www.expertmarketresearch.com/clinical-trials/topical-skin-infection-treatment-drug-pipeline-analysis/requestsample High Incidence of Skin Infections: With nearly 24.8 cases per 1,000 people, skin infections are widespread, driving demand for topical treatments.

Increasing Awareness and Hygiene Practices: Improved awareness about skin health has increased the demand for accessible and effective topical treatments. Advancements in Dermatological Research: Continuous research is leading to the development of novel topical formulations with enhanced efficacy and fewer side effects. Market Challenges:

Antibiotic Resistance: The overuse of antibiotics in topical treatments has contributed to antibiotic resistance, reducing treatment effectiveness.

Formulation Challenges for Topical Drugs: Ensuring that drugs penetrate the skin barrier effectively while maintaining stability and effectiveness is challenging. Skin Sensitivities and Allergic Reactions: Some patients experience skin irritation or allergies from topical treatments, limiting their use. Opportunities:

Growth in Natural and Herbal-Based Topical Treatments: There is increasing interest in plant-based and organic formulations that reduce the risk of side effects.

Development of Combination Therapies: Combining antibacterial, antifungal, or anti-inflammatory agents can create broader-spectrum treatments, improving effectiveness.

Trends in Topical Skin Infection Treatment Drug Pipeline Analysis Focus on Antimicrobial Resistance Solutions: Pharmaceutical companies are increasingly focusing on developing drugs that tackle antimicrobial resistance, such as non-antibiotic antimicrobials and combination therapies.

Rise of Plant-Based and Organic Topicals: Consumer demand for natural, chemical-free products is driving research in plant-based and organic treatments that are gentler on the skin and carry fewer side effects.

Innovation in Delivery Mechanisms: New delivery methods, like lipid-based and nanotechnology-based formulations, enhance drug penetration and bioavailability, allowing for better results with lower doses.

Increasing Focus on Pediatrics and Geriatrics: With children under 5 and adults over 65 being more prone to skin infections, there’s a growing emphasis on treatments tailored for sensitive skin, ensuring safety and efficacy for these vulnerable groups.

Segmentation in Topical Skin Infection Treatment Drug Pipeline Analysis By Drug Type:

Antibacterial Agents Antifungal Agents Antiviral Agents Anti-inflammatory Agents By Infection Type:

Bacterial Infections (e.g., impetigo, cellulitis) Fungal Infections (e.g., athlete’s foot, ringworm) Viral Infections (e.g., cold sores, warts) Mixed Infections By Patient Group:

Pediatrics Adults Geriatrics This segmentation allows for targeted treatments that cater to specific infection types and patient groups, meeting diverse needs across age groups and infection profiles.

Growth Analysis of Topical Skin Infection Treatment Drug Pipeline Market Size and Projections: The topical skin infection treatment market is expected to grow significantly over the coming years, driven by increasing cases of skin infections, rising awareness, and advancements in dermatological research.

Key Growth Drivers:

Rising Demand for Over-the-Counter (OTC) Topical Solutions: Increased preference for OTC products enables easy access to treatments for mild infections, contributing to market growth. Growing Healthcare Expenditure: Higher spending on healthcare globally supports the development and accessibility of advanced topical treatments. New Drug Approvals and Clinical Trials: The surge in drug approvals and clinical trials for novel treatments indicates strong growth potential for the market. Market Challenges Affecting Growth: Challenges such as antibiotic resistance and potential adverse reactions may impact market growth, but innovations in drug formulation and alternative treatments offer solutions to overcome these obstacles.

Recent Developments in Topical Skin Infection Treatment Drug Pipeline Analysis Market GlaxoSmithKline: GlaxoSmithKline has been at the forefront of dermatology research, with a focus on developing topical treatments that address a broad range of skin infections with enhanced efficacy. Fraser Health: Fraser Health has invested in clinical trials focused on bacterial skin infections, aiming to reduce the duration and severity of these conditions. Pfizer: Pfizer’s research includes antifungal and antiviral topical formulations, targeting both common and complex infections. Taro Pharmaceuticals USA: Known for its dermatological products, Taro is developing topical treatments with reduced side effects for sensitive and infected skin. These companies are contributing significantly to the advancement of topical skin infection treatments, developing safe and effective options that cater to different patient needs.

Scope of Shock Wave Therapy Device Market Shock wave therapy, traditionally used in orthopedics, is gaining traction in dermatology. This non-invasive therapy uses acoustic waves to stimulate cell regeneration and improve circulation in affected skin areas. While primarily used for wound healing and tissue repair, shock wave therapy is being researched for treating infections by promoting immune response and accelerating recovery.

Scope in Dermatology:

Potential for Skin Infections: Research is underway to determine if shock wave therapy can effectively treat certain types of skin infections or aid in recovery. Applications in Wound Care and Infection Recovery: By enhancing blood flow and promoting healing, shock wave therapy devices may help in cases where infections have led to skin damage.

Shock Wave Therapy Device Market Analysis The shock wave therapy device market is expanding as new applications emerge. The integration of shock wave devices into dermatology could offer an innovative approach to managing chronic or difficult-to-treat skin infections. However, further research is needed to establish the effectiveness of this therapy for topical skin infections specifically.

Key Trends:

Growing Demand in Dermatology and Wound Care: Increased interest in non-invasive treatments boosts the potential for shock wave therapy in skin infection recovery. Advancements in Device Technology: Improvements in shock wave devices, including targeted and portable models, are making this therapy more accessible.

COVID-19 Impact Analysis The COVID-19 pandemic had a dual impact on the topical skin infection treatment market. On one hand, the focus shifted towards infectious disease management, leading to a temporary slowdown in dermatological research. On the other hand, increased awareness of personal hygiene and skin health drove the demand for topical infection treatments.

Key COVID-19 Impacts:

Supply Chain Disruptions: Supply chain challenges temporarily affected the availability of certain topical medications. Increased Focus on Hygiene: The pandemic encouraged individuals to seek out skin infection treatments, boosting demand for OTC and prescription topicals. Acceleration of Digital Health Solutions: Telemedicine enabled patients to consult dermatologists remotely, facilitating continued access to skin infection treatments.

Key Players in the Topical Skin Infection Treatment Drug Pipeline GlaxoSmithKline: Known for its broad range of topical treatments, GlaxoSmithKline focuses on antibacterial and antifungal agents that address common and complex skin infections. Fraser Health: Fraser Health’s clinical trials are geared toward bacterial infection treatments that provide quicker recovery and reduce the risk of complications. Pfizer: With a strong pipeline of antiviral and antifungal agents, Pfizer is targeting a wide array of skin infections, contributing to innovative solutions. Taro Pharmaceuticals USA: Specializing in dermatology, Taro Pharmaceuticals is advancing in the development of low-irritant, high-efficacy topical formulations. These companies are at the forefront of research and innovation in the topical skin infection treatment pipeline, addressing a broad spectrum of needs across demographics and infection types.

FAQ on Topical Skin Infection Treatment Drug Pipeline Analysis Q1: What is a topical treatment for skin infections? A1: Topical treatments for skin infections include creams, ointments, and gels applied directly to the skin to treat bacterial, fungal, or viral infections.

Q2: Why are children and elderly individuals more prone to skin infections? A2: Children have underdeveloped immune systems, and elderly individuals often have weakened immunity, making them more susceptible to skin infections.

Q3: What are the main types of drugs in the topical skin infection treatment pipeline? A3: Key drug types include antibacterial, antifungal, antiviral, and anti-inflammatory agents, each targeting specific infection types.

Q4: What role does GlaxoSmithKline play in skin infection treatment? A4: GlaxoSmithKline is a leading player in dermatology, developing effective topical treatments for a range of skin infections.

Q5: How did COVID-19 affect the topical skin infection treatment market? A5: COVID-19 disrupted supply chains and shifted focus to infectious disease management but also raised awareness about personal hygiene, increasing demand for topical skin infection treatments.

Q6: Can shock wave therapy be used to treat skin infections? A6: While primarily used for wound healing, shock wave therapy is being researched for its potential in infection recovery by promoting circulation and immune response.

[industrynewsupdates]

Genomics Market Business Growth, Opportunities and Forecast 2024-2030

The global genomics market size was valued at USD 32.65 billion in 2023 and is projected to witness a compound annual growth rate (CAGR) of 16.5% from 2024 to 2030. 

The growth of genomics market is attributed to factors such as growing demand for gene therapy, personalized medicine, drug discovery, increasing cancer incidence, and a significant increase in demand for consumer genomics in recent years. Moreover, increasing number of joint ventures and partnerships amongst market players is also expected to have a positive impact on the genomics market growth. For instance, in June 2022, Illumina, Inc., and Allegheny Health Network signed a collaboration for effective evaluation of the impact of in-house Comprehensive Genomic Profiling (CGP) to leverage patient care.

Gather more insights about the market drivers, restrains and growth of the Genomics Market 

The COVID-19 pandemic outbreak had posed challenges to applications of genomics technology in terms of research and therapeutics. Nevertheless, some niche applications were of great use to mankind during the pandemic situation to facilitate immediate attention for designing effective diagnostics, effective therapeutics and steps to curb the spread of COVID-19.  For example, the viral genome mutational rate (~1-2 bases per month) was gauged for validity of PCR cycle was estimated to understand the efficacy of the re-purposed anti-viral treatments and thereby the vaccine development process was streamlined.

Many genomic surveillance programs were launched country wise to understand the dynamics of pandemic situation and to effective preventive measures. For instance, in December 2020, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) was launched by the joint efforts of Department of Biotechnology (DBT), Ministry of Health, and ICMR with an aim to screen the genomic variations in the SARS-CoV-2 by sequencing technologies. Furthermore, country specific companies are providing consumer genomics services which is also expected to fuel the market size in coming years. One such company being Mapmygenome which is one of the pioneers in India offers DTC genomics services.

The increasing prevalence of inherited cancers is expected create a high demand for cancer genomics. The substantial understanding of human genome have targeted focus on use of various gene therapies for treatment of cancers by modern gene editing techniques such as CRISPR-Cas gene technology. For instance, in September 2022, a group of researchers at the University of California introduced the applications of precision genome editing agents for management of inherited retinal diseases (IRDs).

The development of high-throughput sequencing technologies such as Next-Generation Sequencing (NGS) and microarrays has generated massive amounts of genomic data. However, the rapid accumulation of this data from DNA sequencing and Electronic Health Records (EHRs) poses significant challenges and opportunities for the extraction of biologically or clinically relevant information. Phenome-wide association study (PheWAS) & genome-wide association study (GWAS) are helping researchers to study correlations between genotype and phenotype.

The market players are extensively working towards collaborations, expansions, acquisitions and huge capital investments to advance in research to understand rare diseases and to aid drug discovery. For instance, PacBio declares a collaboration with the Genomics England society for the utility of PacBio’s technology to detect genetic variation in unexplained rare disorders. The study is intended to re-sequence a selection of samples collected during Genomics England’s 100,000 genomes project to discover potential operational and clinical benefits of long-read sequencing for the identification of mutations associated with rare diseases.

Genomics Market Segmentation

Grand View Research has segmented the global genomics market based on application, technology, deliverables, end-use, and region:

Application & Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Functional Genomics

• Transfection

• Real-Time PCR

• RNA Interference

• Mutational Analysis

• SNP Analysis

• Microarray Analysis

• Epigenomics

• Bisulfite Sequencing

• Chromatin Immunoprecipitation (ChIP & ChIP-Seq)

• Methylated DNA Immunoprecipitation (MeDIP)

• High-Resolution Melt (HRM)

• Chromatin Accessibility Assays

• Microarray Analysis

• Pathway Analysis

• Bead-Based Analysis

• Microarray Analysis

• Real-time PCR

• Proteomics Tools (2-D PAGE; yeast 2-hybrid studies)

• Biomarker Discovery

• Mass Spectrometry

• Real-time PCR

• Microarray Analysis

• Statistical Analysis

• Bioinformatics

• DNA Sequencing

• Others

Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Sequencing

• PCR

• Flow Cytometry

• Microarrays

• Other technologies

Deliverables Outlook (Revenue, USD Billion, 2018 - 2030)

• Products

o Instruments/Systems/Software

o Consumables & Reagents

• Services

o NGS-based Services

o Core Genomics Services

o Biomarker Translation Services

o Computational Services

o Others

End-use Outlook (Revenue, USD Billion, 2018 - 2030)

• Clinical Research

• Academic & Government Institutes

• Hospitals & Clinics

• Pharmaceutical & Biotechnology Companies

• Other End Users

Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o India

o Japan

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East & Africa

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global cell sorting market size was valued at USD 242.7 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2030. 

• The global live cell imaging market size was valued at USD 2.48 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2030.

Key Companies & Market Share Insights

The market players operating in the genomics market are adopting product approval to increase the reach of their products in the market and improve the availability of their products & services in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Key Genomics Companies:

• Agilent Technologies

• Bio-Rad Laboratories, Inc.

• BGI Genomics

• Color Genomics, Inc.

• Danaher Corporation

• Eppendorf AG

• Eurofins Scientific

• F. Hoffmann-La Roche Ltd.

• GE Healthcare

• Illumina, Inc.

• Myriad Genetics, Inc.

• Oxford Nanopore Technologies

• Pacific Biosciences of California, Inc.

• QIAGEN N.V.

• Quest Diagnostics Incorporated

• Thermo Fisher Scientific, Inc.

• 23andMe, Inc.

Recent Development

• In November 2023, Fabric Genomics collaborated with DNAnexus and Oxford Nanopore Technologies for deployment of CLIA/CAP labs in pediatric and neonatal ICU’s. The labs will use Oxford Nanopore’s platforms to study genetic disorders in infants.

• In February 2023, Illumina, Inc. entered into a collaboration with African Centre of Excellence for Genomics of Infectious Diseases to start a training institute to increase genomic capabilities in African region

• In January 2023, SOPHiA GENETIC collaborated with the Memorial Sloan Kettering Cancer Center (MSK), a U.S. Cancer Center, to offer researchers and clinicians solutions to expand analytical and testing capabilities.

• In January 2023, Agilent Technologies, Inc. announced acquisition of Avida Biomed, a company that develops target enrichment workflows for clinical researchers utilizing NGS methods to study cancers.

• In April 2022, QIAGEN launched the Biomedical Knowledge Base in Europe, Japan, North America, and Australia to support data science applications in biotech companies 

Order a free sample PDF of the Genomics Market Intelligence Study, published by Grand View Research.

[medicineforcare]

Levoquin 500mg

Levoquin 500 MG is an antibacterial medicine containing 500MG of Levofloxacin as the main ingredient. Levoquin 500MG can help in the treatment of different types of bacterial infections and stop the growth of bacteria in the body.

Levoquin 500 MG is a higher dosage version of Levoquin 250 MG which means that it contains more amount of Levofloxacin ingredients so it’s recommended for severe infections or the age of the patient. Use it with the prescription of the doctor.

Levoquin 500MG is a specialist in the treatment of infections like respiratory issues, urinary tract infections, bone and joint infections, and more.

Levoquin 500MG is the most efficient antibiotic that can stop the growth and duplication of bacteria by killing the enzymes that are responsible for these actions. Levoquin 500 MG is very helpful in treating the infection without feeling any sort of pain or reaction but as it is a prescription medicine hence you need to consult a healthcare specialist before taking it.

If you are taking viral care medicine for the first time then start with smaller doses of Levoquin 250mg and higher doses are also available Levoquin 500mg. We are also providing medicines like Cefix 200mg, Claribid 250mg, Naprosyn 250mg, and Bactrim D.S.

Why you must consider Levoquin 500 MG?

Levoquin 500 MG is one of the best products of the Levofloxacin category available in the market right now and it is one of the products that have the least side effects. Secondly is the effectiveness and relief that it gives to the patient taking it.

Some Interesting Insights About Levoquin 500 MG?

Levofloxacin:

Levofloxacin is an antibacterial ingredient that is used to prevent bacteria to grow or reproduce in the body. Levofloxacin works by killing the enzymes of bacteria that are responsible for growth and reproduction. Levofloxacin is a broad-spectrum antibiotic that can help to treat bacterial infections. It comes from antibiotics class called fluoroquinolone and works by inhibiting the bacterial DNA replication and cell division process, which ultimately leads to bacterial cell death. Levofloxacin is commonly used to treat breathing infections, like pneumonia, bronchitis, & sinusitis. It can also treat skin and soft tissue infections, urinary tract infections, and bone and joint infections. Levofloxacin is usually taken orally, but it can also be given intravenously for severe infections. The type and severity of the infection being treated can determine the dosage and duration of treatment, as well as the age of the patient and previous medical conditions. Like all antibiotics, levofloxacin can cause side effects, including nausea, diarrhea, headache, dizziness, and photosensitivity. In infrequent cases, People reported serious side effects such as tendon rupture, nerve damage, and allergic reactions. It is important to take levofloxacin exactly as prescribed by a healthcare provider and to report any unusual symptoms or side effects immediately.

Levoquin 500 MG:

Levoquin 500 MG is an economical anti-bacterial that basically contains 250 MG of levofloxacin which belongs to a specific class of drugs used in antibiotics. Levofloxacin retains in the body of organisms for longer time periods and effectively treats infections. Due to the wide range of levofloxacin’s ability to kill bacteria including both gram-negative and gram-positive bacteria Levoquin 500 MG becomes a more effective medication.

How does Levoquin 500 MG work?

Levoquin 500 MG has 500 MG of Levofloxacin so it works by killing the bacterial enzymes that have the ability to grow or replicate themselves. Levoquin 500 MG prevent them to grow and spread in the body. Levoquin 500 MG also kills the bacterial enzymes that can duplicate them.

How should I get a Levoquin 500 MG?

Levofloxacin is a commonly prescribed medicine hence it is available in all the local pharmacies and you can get them online as well but the website that showcases Levoquin 500MG at the best price is MedzBuddy.com where you can find Levoquin 500MG at the best price available and in bulk as well. It is an emerging online platform that provides its customers with a wide range of generic medicines making the purchase of medicines easy and time-saving.

But for the purchase of Levoquin 500MG, you should have a prescription from a health care consultant that makes its purchase valid. Levofloxacin is a prescription medication, which means you will need to consult with a healthcare professional, such as a doctor or a pharmacist, who can evaluate your medical condition and determine if Levofloxacin is an appropriate treatment option for you. If your healthcare professional determines that Levofloxacin is appropriate for your medical condition, they can provide you with a prescription, and you can obtain Levofloxacin from a pharmacy.

Side Effects of Levoquin 500 MG

Levoquin 500 MG has different side effects in different types of individuals. That includes

Nausea

Headache

Dizziness

Diarrhea

Vomiting

Difficulty in Sleeping

Some rare side effects include:

Tendonitis

Tendon Rupture

Liver Problem

[colinwilson11]

The Non-Viral Drug Delivery Systems Market To Grow Owing To Increasing Advantages Over Viral Delivery Methods

Non-viral drug delivery systems have gained immense popularity in recent years owing to their advantages over viral delivery methods including low immunogenicity, larger transgene capacity and ease of production. Non-viral techniques involve encapsulating drugs into nanoparticles, liposomes or conjugating them to targeting moieties and are generally considered safer than viral vectors.

The Non-Viral Drug Delivery Systems Market is estimated to be valued at US$ 8.1 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the non-viral drug delivery systems market are Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, eTheRNA Immunotherapies. The companies are investing heavily in R&D to develop novel non-viral vectors with higher efficiency and safety. The growing demand for targeted drug delivery systems is a major factor driving the non-viral drug delivery systems market. Non-invasive therapeutic delivery through oral, transdermal and inhalation routes has gained prominence. Technological advancements like lipid nanoparticles, polymeric nanoparticles and conjugation with cell-penetrating peptides have increased the delivery of macromolecules.

Market Trends

One of the major trends in the non-viral drug delivery systems market is the rising focus on gene therapy. Non-viral gene delivery methods offer less immunogenic and inflammatory responses making them safer for repeated administration. mRNA-based therapies and applications in cancer immunotherapy are emerging as lucrative opportunities. Another key trend is the development of stimuli-responsive delivery systems that are designed to release drug payloads in response to specific biochemical cues like pH, redox potential or enzymatic activity at the site of action.

Market Opportunities

Targeted delivery to tumors using actively/passively targeted nanoparticles presents a huge opportunity. The application of nanotechnology has allowed efficient delivery of anti-cancer drugs, imaging agents and nucleic acids selectively to tumor tissues. Oligonucleotide therapeutics also offer lucrative opportunities given the advances in mRNA vaccines. Non-invasive delivery through pulmonary route for treatment of lung cancers and respiratory diseases is an emerging area of focus.

Impact Of COVID-19 On Non-Viral Drug Delivery Systems Market Growth

The COVID-19 pandemic has significantly impacted the non-viral drug delivery systems market. During the initial phases of the pandemic, most non-essential research was put on hold or delayed, impacting the development of new drug delivery technologies. Companies focused their efforts on developing COVID-19 vaccines and therapeutics to address the urgent medical need. This diverted resources away from other drug delivery applications.

However, as the pandemic progressed, companies recognized the long-term market potential for non-viral delivery platforms to address future pandemics and other diseases. Nanoparticle-based delivery systems can effectively transport mRNA, DNA and protein therapeutics into cells, making them well-suited for developing new classes of antiviral drugs and vaccines. Several companies utilized their non-viral platforms to design COVID-19 vaccines and therapies during clinical trials.

Going forward, governments and healthcare agencies are expected to prioritize research into development capabilities for rapid responses to health emergencies. Non-viral delivery technologies can play a major role here through their ability to package different types of biologics and enable faster discovery processes compared to viral vectors. Companies are also advancing formulations tuned for stability at varying temperatures and extended shelf-life to address logistical challenges in vaccine distribution globally.

North America Dominates Non-Viral Drug Delivery Systems Market

The North America region currently dominates the Non-Viral Drug Delivery Systems Market in terms of value. This is due to presence of established pharmaceutical and biotechnology companies engaged in development and commercialization of delivery platforms for various biologics. Large companies have made significant investments setting up research centers focused on non-viral technologies.

Government funding for innovation is also strong through the National Institute of Health and Department of Defense programs. Academic research is rapidly advancing new formulations and delivery routes. The U.S. and Canada also have a well-developed regulatory system to approve new drug-device combination products incorporating non-viral carriers. High healthcare spends per capita contribute to faster market uptake of advanced therapeutics enabled by these platforms.

Asia Pacific Emerging As Fastest Growing Region

Going forward, the Asia Pacific region is expected to offer the fastest market growth opportunities for non-viral drug delivery systems. This is attributable to rising chronic disease prevalence in highly populated countries like China and India. Governments are investing significantly to build local R&D capabilities through initiatives such as the Made in China 2025 policy.

Countries like South Korea and Japan also have large biotechnology industries focusing on formulations. At the same time, reduced manufacturing and labor costs are attracting global pharmaceutical companies to outsource production to Asia Pacific contract development and manufacturing organizations. This will help expand regional production capacities for various non-viral technologies.

Get more insights on this topic:  https://www.ukwebwire.com/non-viral-drug-delivery-systems-market-are-estimated-to-witness-high-growth-owing-to-advancements-in-nanotechnology/

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)

What Are The Key Data Covered In This Non-Viral Drug Delivery Systems Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Non-Viral Drug Delivery Systems Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Non-Viral Drug Delivery Systems Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Non-Viral Drug Delivery Systems Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Non-Viral Drug Delivery Systems Market vendors

FAQ’s

Q.1 What are the main factors influencing the Non-Viral Drug Delivery Systems Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Non-Viral Drug Delivery Systems Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Non-Viral Drug Delivery Systems Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it